News

Is Cancer Research Being Abandoned By The Public Sector?
As diagnoses climb and innovation accelerates, major federal funding cuts are forcing a shift toward private biotech - and ...
C&EN19d
Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 Interaction
Comprehensive Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, and Life Sciences Institute, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, ...
C&EN22d
Harnessing Fluorine–Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs
⊥ Institute of Pharmaceutical Chemistry, Johann Wolfgang Goethe-University and Buchmann Institute for Molecular Life Sciences, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany *Tel.: +44-1273 ...
New Atlas23d
How elephants evolved to beat cancer, and how we could too
Elephants seem to have 20 different copies of a tumor-suppressing gene known as p53. This gene encodes a protein, also known as p53, which serves as a crucial cell protector. This protein acts a ...
BioWorld23d
Other news to note for May 21, 2025
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Akoya, Konica Minolta Healthcare, Medithinq, Newvue, Philips ...
BioWorld23d
CSIC divulges new antiviral compounds for coronavirus acute respiratory syndrome
Scorpion Therapeutics patents p53 Y220 mutant activators BioWorld Science Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) ...